Wedbush Maintains Neutral on Vor Biopharma, Raises Price Target to $27

Benzinga Newsdesk www.benzinga.com Positive 60.5%

Neg 0% Neu 0% Pos 60.5%

Wedbush analyst Martin Fan maintains Vor Biopharma (NASDAQ:VOR) with a Neutral and raises the price target from $18 to $27.